Pretax income is the income that a company earns before paying income taxes. Allakos's pretax income for the
three
months ended in Dec. 2023 was $-62.55 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-185.70 Mil.
Allakos's pretax margin was %.
Allakos Pre-Tax Income Historical Data
The historical data trend for Allakos's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allakos's Pre-Tax Income
For the Biotechnology subindustry, Allakos's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allakos's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allakos's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Allakos's Pre-Tax Income falls into.
Allakos Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Allakos's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-185.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allakos (NAS:ALLK) Pre-Tax Income Explanation
Allakos's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allakos Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Allakos's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLK has been successfully added to your 